Esperion Therapeutics (ESPR) News Today $1.00 0.00 (-0.34%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$0.99 0.00 (-0.17%) As of 04/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Vanguard Group Inc. Has $25.78 Million Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR)Vanguard Group Inc. cut its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 10.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,715,748 shares of the biopharmaceutical company's stock afteApril 16 at 3:19 AM | marketbeat.comCenterBook Partners LP Has $2.87 Million Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)CenterBook Partners LP lowered its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 58.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,306,259 shares of the biopharmaApril 12, 2025 | marketbeat.comEsperion to host R&D Day to highlight cardiometabolic pipelineApril 11, 2025 | markets.businessinsider.comEsperion Therapeutics' (ESPR) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $5.00 price objective on shares of Esperion Therapeutics in a report on Tuesday.April 10, 2025 | marketbeat.comEsperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025April 10, 2025 | globenewswire.comEsperion (ESPR) Gets a Buy from NeedhamApril 8, 2025 | markets.businessinsider.comEsperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound?April 3, 2025 | msn.comEsperion appoints Hoffman to board of directorsApril 2, 2025 | markets.businessinsider.comDiametric Capital LP Sells 312,829 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)Diametric Capital LP lessened its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 46.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 354,010 shares of the biopharmaceutical company's stock after selling 312,829 shares durinApril 2, 2025 | marketbeat.comEsperion Appoints Robert E. Hoffman to Board of DirectorsApril 1, 2025 | globenewswire.comZacks Research Issues Negative Outlook for ESPR EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, March 25th. Zacks Research analyst K. Das now forecasts that the biopharmaceuMarch 29, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of "Moderate Buy" by AnalystsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a holMarch 29, 2025 | marketbeat.comWhat is Zacks Research's Estimate for ESPR FY2027 Earnings?Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Investment analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a note issued to investors on Tuesday, March 25th. Zacks Research analyst K. Das expects that the biopharmaMarch 28, 2025 | marketbeat.comEsperion to Participate in 24th Annual Needham Virtual Healthcare ConferenceMarch 24, 2025 | markets.businessinsider.comVictory Capital Management Inc. Increases Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)Victory Capital Management Inc. boosted its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 602.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 173,083 shares of the biMarch 23, 2025 | marketbeat.comEsperion aligns with U.S. FDA to initiate Phase 3 trials of bempedoic acidMarch 21, 2025 | markets.businessinsider.comEsperion Therapeutics (NASDAQ:ESPR) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Thursday.March 21, 2025 | marketbeat.comPlatinum Investment Management Ltd. Sells 252,810 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)Platinum Investment Management Ltd. cut its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 23.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 840,052 shareMarch 20, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Acquired by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 31.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 932,008 shares ofMarch 19, 2025 | marketbeat.comESPR FY2025 EPS Estimate Boosted by Cantor FitzgeraldEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities research analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a note issued to investors on Wednesday, March 12th. Cantor Fitzgerald analyst K. Kluska now antiMarch 15, 2025 | marketbeat.comQ3 Earnings Forecast for ESPR Issued By HC WainwrightEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Investment analysts at HC Wainwright issued their Q3 2025 EPS estimates for Esperion Therapeutics in a report issued on Tuesday, March 4th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will earn ($0.15)March 8, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for ESPR Q1 Earnings?Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, March 4th. HC Wainwright analyst J. Pantginis expects that the biopharmaceuMarch 7, 2025 | marketbeat.comEsperion Bags $5 Mln CSL Seqirus Deal To Commercialize Cholesterol Drugs In Australia, New ZealandMarch 5, 2025 | nasdaq.comEsperion Therapeutics' (ESPR) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $16.00 target price on shares of Esperion Therapeutics in a report on Tuesday.March 5, 2025 | marketbeat.comEsperion reports Q4 EPS (11c), consensus (16c)March 4, 2025 | markets.businessinsider.comEsperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | seekingalpha.comEsperion Therapeutics (NASDAQ:ESPR) Releases Earnings Results, Beats Estimates By $0.04 EPSEsperion Therapeutics (NASDAQ:ESPR - Get Free Report) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.04.March 4, 2025 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPSEsperion Therapeutics (NASDAQ:ESPR - Get Free Report) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.04.March 4, 2025 | marketbeat.comEsperion Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 4, 2025 | globenewswire.comEsperion Therapeutics Q4 2024 Earnings PreviewMarch 3, 2025 | msn.comEsperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in AustraliaMarch 3, 2025 | globenewswire.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Rating of "Moderate Buy" by BrokeragesEsperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) has received a consensus rating of "Moderate Buy" from the six brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recoMarch 3, 2025 | marketbeat.comIs Esperion Therapeutics, Inc. (ESPR) the Best Small Cap Pharma Stocks to Buy Now?March 1, 2025 | msn.comSigma Planning Corp Increases Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)Sigma Planning Corp boosted its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 1,455.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 190,441 shares of the biopharmaceutical company's stFebruary 28, 2025 | marketbeat.comEsperion Therapeutics: Little Upside Potential In Their Earlier Generation DrugFebruary 22, 2025 | seekingalpha.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest UpdateEsperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) saw a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 31,240,000 shares, a decrease of 8.1% from the January 15th total of 33,980,000 shares. Currently, 16.0% of the shares of the company are sold short. Based on an average trading volume of 6,230,000 shares, the days-to-cover ratio is presently 5.0 days.February 18, 2025 | marketbeat.comEsperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4February 18, 2025 | globenewswire.comEsperion Therapeutics (ESPR) Expected to Announce Earnings on TuesdayEsperion Therapeutics (NASDAQ:ESPR) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18, 2025 | marketbeat.comZacks Research Has Negative Forecast for ESPR Q3 EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Investment analysts at Zacks Research lowered their Q3 2025 EPS estimates for shares of Esperion Therapeutics in a research note issued on Wednesday, February 12th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical cFebruary 17, 2025 | marketbeat.comEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)February 13, 2025 | globenewswire.comEsperion Therapeutics' (ESPR) Market Outperform Rating Reaffirmed at JMP SecuritiesJMP Securities reissued a "market outperform" rating and issued a $4.00 price objective (down from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday.February 11, 2025 | marketbeat.comEsperion price target lowered to $4 from $7 at JMP SecuritiesFebruary 11, 2025 | markets.businessinsider.comEsperion stock target cut to $4 by JMP SecuritiesFebruary 11, 2025 | msn.comEsperion stock holds Buy rating, $16 target from H.C. WainwrightFebruary 11, 2025 | msn.comEsperion Therapeutics' (ESPR) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Tuesday.February 11, 2025 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from AnalystsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a holFebruary 6, 2025 | marketbeat.comEsperion (ESPR) Receives a Sell from Bank of America SecuritiesFebruary 4, 2025 | markets.businessinsider.comWhat is HC Wainwright's Estimate for ESPR FY2028 Earnings?Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Stock analysts at HC Wainwright cut their FY2028 EPS estimates for Esperion Therapeutics in a report released on Thursday, January 23rd. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will earn $0.16January 27, 2025 | marketbeat.comCautious Outlook on Esperion: Sell Rating Amid Market Challenges for Bempedoic AcidJanuary 23, 2025 | markets.businessinsider.comPromising Potential of Esperion’s Non-Statin Drugs in Cardiovascular Disease ManagementJanuary 23, 2025 | markets.businessinsider.com Remove Ads Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address ESPR Media Mentions By Week ESPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESPR News Sentiment▼0.790.79▲Average Medical News Sentiment ESPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESPR Articles This Week▼54▲ESPR Articles Average Week Remove Ads Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Avid Bioservices News Today Spyre Therapeutics News Today Intellia Therapeutics News Today Vir Biotechnology News Today Zymeworks News Today Nurix Therapeutics News Today Avadel Pharmaceuticals News Today Anavex Life Sciences News Today Oculis News Today Day One Biopharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ESPR) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
